AI assistant
Traws Pharma, Inc. — Director's Dealing 2013
Jul 25, 2013
35199_dirs_2013-07-24_8a989e35-08a4-4a7c-8a89-1390116fdd90.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2013-07-24
Reporting Person: BANSAL AJAY (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 20061 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Convertible Preferred Stock | $ | Common Stock (28181) | Direct | ||
| Stock Option (right to buy) | $13.28 | 2023-03-21 | Common Stock (135033) | Direct |
Footnotes
F1: Includes 806 shares held jointly with spouse.
F2: The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.85-for-1 basis and has no expiration date.
F3: This option, representing a right to purchase a total of 135,033 shares of Common Stock, is immediately exercisable and vests over 4 years from March 20, 2013, with 25% vesting on March 20, 2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.